

香港聯合交易所有限公司

(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

ANNOUNCEMENT

In relation to the matter of
Baytacare Pharmaceutical Co., Ltd (the “Company”)
(Incorporated in the People’s Republic of China with limited liability)
(Stock Code: 8197)

Cancellation of listing

The Stock Exchange of Hong Kong Limited (the “Exchange”) announced that with effect from 9:00 am on 18 March 2020, the listing of the shares of Baytacare Pharmaceutical Co., Ltd (the “Company”) will be cancelled under GEM Rule 9.14A.

The Exchange announces that the listing of the Company's shares will be cancelled with effect from 9:00 am on 18 March 2020 under GEM Rule 9.14A.

Trading in the Company's shares has been suspended since 27 September 2018. Under GEM Rule 9.14A, the Exchange may delist the Company if trading does not resume by 26 September 2019.

The Company failed to resume trading by 26 September 2019. On 15 November 2019, the GEM Listing Committee decided to cancel the listing of the Company's shares on the Exchange under GEM Rule 9.14A.

On 22 November 2019, the Company sought a review of the delisting decision by the GEM Listing Review Committee. On 5 March 2020, the Listing Review Committee upheld the GEM Listing Committee's decision to cancel the listing of the Company's shares on the Exchange. Accordingly, the Exchange will cancel the Company's listing with effect from 9:00 am on 18 March 2020.

The Exchange has requested the Company to publish an announcement on the cancellation of its listing.

The Exchange advises shareholders of the Company who have any queries about the implications of the delisting to obtain appropriate professional advice.

Hong Kong, 16 March 2020